引下げ薬の英語

1990、1991 以降、薬価の引下げ等により国民医療費に占める薬剤費比率は約30％から約20％へ低下してきたが、直近5年間で見ると、薬剤費比率はやや持ち直している。（図表 4、5）。例文帳に追加

After 1990 and 1991, the percentage of the drug cost in the medical care expense for citizens has decreased from about 30% to about 20% due to reduction of drug price, etc. but in this 5 years, the percentage of the drug cost slightly takes a favorable turn (Figs. 4 and 5). - 厚生労働省

この近年の縮小傾向は、概ね２年ごとに行われる薬価改定(引下げ)が大きく影響しているものと考えられるが、薬価差の縮小、医薬品の適正使用の普及、新薬の登場等により薬剤費比率は下げ止まっている状況にある。例文帳に追加

This tendency toward decrease in recent years would have received large influence of drug price revision (reduction) conducted almost every two years but it is the situation that the percentage of drug cost stops to decrease from decrease of drug price difference, repercussion of proper use of pharmaceutical products and appearance of few drugs, etc. - 厚生労働省

薬価制度については、医薬品産業の振興及び発展という観点から、薬価基準の下では継続的に価格が下がり続ける、先発医薬品の特例引下げなどの市場価格に依らない仕組みは健全な競争を阻害する等の指摘がされている。例文帳に追加

Acceleration of approval reviews The problems with the drug pricing system in terms of promoting and expanding the drug industry have been referred to. These include the impediment to healthy competition of a system in which prices fall continuously under the drug pricing criteria and special case reductions of original drugs etc. that are independent of market prices. - 厚生労働省

他方、日本企業においては、国内の薬価引下げや医療費抑制策による経営環境の悪化、バイオ医薬品等の研究開発費の巨大化等を背景に、今までの経営手法では成長が望めなくなり、かつ外資の力に圧倒され、守勢に回らざるを得ない状況になった。例文帳に追加

Meanwhile, Japanese companies were faced with a situation in which they had little chance of achieving growth through current management methods,with a deteriorating business environment caused by drug price falls and medical fee restriction measures as well as escalating R&D fees for bio medicine. Overwhelmed by the power of foreign affiliates, Japanese companies had no choice but to take a defensive position. - 経済産業省

この観点からみると、現在の薬価制度の下では、特許期間中でも薬価が継続的に下落し得る構造になっており、また、そのような価格を比較対照として薬価を算定した場合、加算後の薬価であっても欧米主要国の新薬の薬価水準よりも低い傾向があり、外国平均格調整で引下げとなる場合よりも引上げとなる場合が多くなる傾向がある。このように、海外で我が国よりも高い薬価が期待できる医薬品については、海外で先に上市した方が薬価算定に有利であり、国内先行開発に不利な算定方式になっている等の指摘がある。例文帳に追加

From this perspective, given the situation under the present drug pricing system where, even during the patent life, drug prices are structured to fall continuously and moreover are used for comparison in the calculation of drug prices, even the corrected prices of new drugs are likely to fall below the level in the major European countries and the US, leading to more increases rather than reductions on the application of the foreign price adjustment. In respect of drugs which thus are expected to be more highly priced abroad than in Japan, it has been pointed out that launch overseas gives more favorable drug pricing and that the pricing system has become unfavorable to domestic lead-off development. - 厚生労働省